Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin

The Prostate
S BesharaB G Danielson

Abstract

Nine patients with hormone-refractory metastatic prostatic adenocarcinoma and anemia were treated with recombinant human erythropoietin (rHuEpo) at a median dose of 150 U/kg BW 3 times a week subcutaneously. Baseline hemoglobin (Hb) ranged from 70 to 116 g/L, and the study duration was 12 weeks (median patient participation period was 8 weeks). Four patients demonstrated a median Hb increase of 20 g/L and were considered responders. Three patients showed a median increase of 17 g/L but required blood transfusion once, and were therefore considered as partial responders. Baseline erythropoietic status showed a significant correlation between serum Epo and Hb. Inadequate Epo production, evaluated by the observed/predicted log Epo ratio, was found in two patients. Defective bone marrow activity, demonstrated by low transferrin receptor (TfR), and hypoferremia in spite of abundant iron stores were also shown. Hemorheological investigations showed elevated plasma viscosity. Our results indicate that suppression of erythropoiesis can be mainly explained by the depressed marrow activity. The altered hemorheology might contribute to the anemia. This anemia could possibly be corrected with rHuEpo.

References

Mar 1, 1992·British Journal of Haematology·M Cazzola, Y Beguin
Oct 1, 1991·Annals of Internal Medicine·R F Schilling
Nov 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L C PlataniasM J Ratain
May 9, 1991·The New England Journal of Medicine·A J Erslev
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W OsterR Mertelsmann
Jun 14, 1990·The New England Journal of Medicine·C B MillerJ L Spivak
Jun 14, 1990·The New England Journal of Medicine·H LudwigU Barnas
Jan 1, 1989·Upsala Journal of Medical Sciences·B Sandhagen
Mar 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D C Doll, R B Weiss
Jan 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S B Krantz
Jan 1, 1993·The Journal of Clinical Investigation·A SinghW H Reinhart
Mar 1, 1993·American Journal of Clinical Pathology·H N RaafR Green

❮ Previous
Next ❯

Citations

Jan 1, 2007·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Pratipal Singh, Aneesh Srivastava
Jul 25, 2007·Clinical Genitourinary Cancer·Tomasz M BeerCelestia S Higano
Jun 11, 1999·The Urologic Clinics of North America·P Esper, B G Redman
Oct 8, 2003·The Oncologist·Carrie A ThompsonCharles L Loprinzi
Nov 18, 2003·BJU International·N W Clarke
Oct 7, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Murat O ArcasoyZishan A Haroon
Nov 13, 2004·The Journal of Laboratory and Clinical Medicine·Des R Richardson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.